KalVista Pharmaceuticals, Inc.
DE ˙ DB ˙ US4834971032
23,01 € 0,00 (0,00%)
2026-06-04
CENA AKCJI
SecurityDE:4XC1 / KalVista Pharmaceuticals, Inc.
InstitutionState Street Corp
Latest Disclosed Ownership1,955,844 shares
Latest Disclosed Value $ 39,371,140
State Street Corp reports 2.31% increase in ownership of 4XC1 / KalVista Pharmaceuticals, Inc.

On May 15, 2026 - State Street Corp filed a 13F-HR form disclosing ownership of 1,955,844 shares of KalVista Pharmaceuticals, Inc. (DE:4XC1) valued at $30,315,582 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 1,911,691 shares of KalVista Pharmaceuticals, Inc.. This represents a change in shares of 2.31% during the quarter. The current value of the position is $45,003,970 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 1,955,844 44,153 2.31 39,371 27.53 0.0014
2026-02-13 2025-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 1,911,691 336,195 21.34 30,874 60.89 0.0010
2025-11-14 2025-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 1,575,496 225,957 16.74 19,190 25.78 0.0007
2025-08-14 2025-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 1,349,539 255,896 23.40 15,257 20.89 0.0006
2025-05-15 2025-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 1,093,643 -297,220 -21.37 12,621 7.13 0.0005
2025-02-14 2024-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 1,390,863 119,254 9.38 11,781 -20.00 0.0005
2024-11-14 2024-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 1,271,609 515,179 68.11 14,725 65.26 0.0006
2024-08-14 2024-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 756,430 162,257 27.31 8,911 26.45 0.0004
2024-05-15 2024-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 594,173 57,071 10.63 7,047 7.10 0.0003
2024-02-14 2023-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 537,102 77,756 16.93 6,580 48.75 0.0003
2023-11-14 2023-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 459,346 13,171 2.95 4,424 10.16 0.0002
2023-08-14 2023-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 446,175 26,914 6.42 4,016 21.85 0.0002
2023-05-15 2023-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 419,261 15,301 3.79 3,295 20.70 0.0002
2023-05-15 2022-12-31 13F/A-99 KALVISTA PHARMACEUTICALS COM 483497103 403,960 -17,859 -4.23 2,731 -55.40 0.0002
2023-05-15 2022-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 403,960 -17,859 2,731 0.0002
2022-11-15 2022-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 421,819 11,567 2.82 6,121 51.62 0.0004
2022-08-15 2022-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 410,252 -528,615 -56.30 4,037 -70.83 0.0002
2022-05-16 2022-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 938,867 -113,109 -10.75 13,839 -0.57 0.0007
2022-02-14 2021-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 1,051,976 8,148 0.78 13,918 -23.59 0.0007
2021-11-15 2021-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 1,043,828 -356,673 -25.47 18,215 -45.72 0.0010
2021-08-16 2021-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 1,400,501 809,029 136.78 33,556 120.84 0.0018
2021-07-09 2021-03-31 13F/A-1 KALVISTA PHARMACEUTICALS COM 483497103 591,472 323,818 120.98 15,195 198.94 0.0009
2021-05-17 2021-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 591,472 323,818 15,195 0.0009
2021-02-16 2020-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 267,654 7,089 2.72 5,083 54.92 0.0003
2020-11-10 2020-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 260,565 8,795 3.49 3,281 7.72 0.0002
2020-08-14 2020-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 251,770 6,769 2.76 3,046 62.54 0.0002
2020-06-19 2020-03-31 13F/A-1 KALVISTA PHARMACEUTICALS COM 483497103 245,001 13,060 5.63 1,874 -54.64 0.0002
2020-05-11 2020-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 245,001 13,060 1,874 164.5749
2020-02-06 2019-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 231,941 3,790 1.66 4,131 56.06 0.0003
2019-11-14 2019-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 228,151 27,325 13.61 2,647 -40.49 0.0002
2019-08-14 2019-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 200,826 192,251 2,241.99 4,448 1,715.51 0.0003
2019-05-15 2019-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 8,575 8,575 245 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.